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ABSTRACT
The C-terminal domain (CTD) of RNA polymerase II
regulates transcription through spatially and temp-
orally coordinated events. Previous work had estab-
lished that the CTD binds DNA but the significance
of this interaction has not been determined. The
present work shows that the CTD binds DNA in its
unphosphorylated form, the form in which it is pres-
ent in the pre-initiation complex. The CTD/DNA
complex is recognized by and is phosphorylated
by Cdk7 but not by Cdk9. Model-building studies
indicate the structural mechanism underlying such
specificity involves interaction of Cdk7 with DNA in
the context of the CTD/DNA complex. The model
has been tested by mutagenesis experiments. CTD
dissociates from DNA following phosphorylation by
Cdk7, allowing transcription initiation. The CTD then
becomes accessible for further phosphorylation
by Cdk9 that drives the transition to transcription
elongation.
INTRODUCTION
Phosphorylation of RNA polymerase II (RNA-Pol II)
carboxy-terminal domain (CTD) by cyclin-dependent
kinase 7 (Cdk7) and cyclin-dependent kinase 9 (Cdk9) in
association with their cyclins regulates transcription and
allows the coordination of transcription with mRNA
maturation. The mechanisms underlying this regulation
are complex. The human CTD comprises 52 repeats
of the heptapeptide Y1S2P3T4S5P6S7 (mostly consensus
at the N-terminal region with divergent repeats located
at the C-terminal region) and is involved in binding with
several proteins. Depending on its phosphorylation state,
the CTD can discriminate among its binding partners and
hence is poised to organize transcription both temporally
and spatially (1).
The unphosphorylated CTD binds proteins of the pre-
initiation complex like the TATA-binding protein (TBP)
(2) and the Mediator complex (3) and is involved in the
assembly of the inactive transcription machinery on the
promoter DNA. Phosphorylation of CTD Ser5 by Cdk7
disrupts those interactions resulting in an active RNA-Pol
II and a scaﬀold complex that remains at the promoter.
Phospho-Ser5 CTD is recognized by the capping enzyme
(4,5). The RNA cap structure is added shortly after tran-
scription initiation, when nascent RNA is about 25–30nt
in length.
Ser5 phosphorylated CTD RNA-Pol II is compe-
tent for initiation of transcription but is unable to
enter the elongation phase and to transcribe the entire
mRNA (6,7). This form of the RNA-Pol II binds the
DRB (5,6-dichlorobenzimidazole 1-b-D-ribofuranoside)-
sensitivity-inducing factor (DSIF) and the negative elon-
gation factor (NELF), the two inhibitors of the elongation
phase of transcription, that lead to generation of abortive
transcripts (8). Inhibition of elongation is removed follow-
ing phosphorylation of DSIF and NELF by Cdk9 (9–11).
Phosphorylation of CTD Ser2 by Cdk9 generates a new
form of the RNA-Pol II, that is recognized by elongation
factors like Elongator and allows the assembly of the
elongation-competent RNA-Pol II (12,13). Moreover the
Ser2-Ser5 phosphorylated CTD is recognized by splicing
factors and is required for assembly of the spliceosome
and for eﬃcient splicing reactions on the elongating
RNA (14). Finally, although polyadenylation, cleavage
and transcription termination requires interactions of the
cleavage/polyadenylation speciﬁcity factor (CPSF) and of
the Cleavage-stimulation Factor (CstF) with CTD these
interactions do not appear to be dependent on the phos-
phorylation status of the CTD (15–17).
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Cdk9 action on CTD requires a mechanism discriminating
between the two kinases (that are present at the same time
in the same location) so that they can never act together
but only sequentially.
The work reported here describes a possible mechanism
starting with the observation that CTD binds DNA in
its unphosphorylated form. The CTD/DNA complex is
recognized by Cdk7 that can then phosphorylate Ser5.
This releases the CTD from the DNA and makes it avail-
able for Cdk9 phosphorylation. A structural model for
CTD/DNA recognition by Cdk7 is proposed and tested
with mutagenesis studies.
MATERIALS AND METHODS
Protein production and mutagenesis
Cdk7, Cdk7/CycH and Cdk9-330/CycT1-298 were pro-
duced in baculo-viral-infected insect cells as previously
described (18,19). Cdk9-330 (residues 1–330) corresponds
to the Cdk9 kinase domain. CycT1-298, corresponding
to residues 1–298, contains the two cyclin boxes required
for Cdk9 activation.
Mutagenesis for pCdk2 were performed using the
‘Site Directed Mutagenesis Kit’ (Stratagene, La Jolla,
CA, USA) and following manufacturer’s instructions.
Unphosphorylated Cdk2, WT-pCdk2, pCdk2 mutants,
CycA, pCdk2/CycA and pCdk2/CycA mutants were pur-
iﬁed as previously described (20).
Cdk7/CycA was obtained by immobilizing GST-Cdk7
on glutathione-sepharose and binding CycA from the
CycA-expressing Escherichia coli lysate. Elution was per-
formed with GST-3C protease that removed the GST tag
from Cdk7.
pCdk2/CycH and its mutants were obtained by immo-
bilizing GST-pCdk2 or GST-pCdk2 mutants on glutathio-
ne-sepharose and binding CycH from the CycH-
expressing E. coli lysate. Elution was performed with
GST-3C protease.
Human CTD (comprising all 52 repeats) was expressed
as N-terminal GST-fusion protein and puriﬁed as pre-
viously described (18). pSer5-GST-CTD was obtained
incubating 30mg of GST-CTD with 0.3mg of Cdk7/
CycH in 50mM Tris pH 8, 10mM MgCl2 and 0.1mM
ATP for 2h at RT. Cdk7/CycH was then removed by
immobilizing pSer5-GST-CTD on glutathione-sepharose
and extensively washing. pSer5-GST-CTD was eluted
with 10mM glutathione.
Kinase assays
Cdk7/CycH, Cdk9-330/CycT1-298, Cdk7/CycA, pCdk2/
CycA pCdk2/CycH and pCdk2 mutants in complex with
CycA or CycH activities were measured by following the
incorporation of radiolabeled phosphate into substrate.
GST-CTD (5mg), alone or in complex with DNA, was
incubated with 100ng of the diﬀerent Cdk/cyclin com-
plexes in 10ml kinase buﬀer [0.1mM ATP, 10mM
MgCl2, 50mM Tris/HCl pH 7.5, 1mCi g-32P-labeled
ATP (MP Biomedicals)]. The reaction mixtures were
incubated for 5min at 208C and terminated by the addi-
tion of SDS sample buﬀer. Samples were analyzed on
SDS–PAGE gels and visualized by autoradiography.
All reactions were performed in duplicate.
For the GST–CTD/DNA complex, GST-CTD
samples (5mg=60pmol) were previously mixed with
200pmol of double-stranded DNA for single-point
experiments or with 12, 60, 300 or 1500pmol for titration
experiments. Oligonucleotides (45nt each: GTTACTTCT
ATGCCTGATTACGTCAGTTTCCCCAAGTGGGCC
CGG and CCGGGCCCACTTGGGGAAACTGACGT
AATCAGGCATAGAAGTAAC) were annealed in
10mM Tris pH 8, 50mM NaCl prior to incubation
with GST–CTD in 20mM Tris pH 8, 20mM NaCl,
1mM MgCl2 in ice for 30min. Same conditions were
used to test the phosphorylating activity of Cdk7/CycH
on Cdk2.
Pixels were quantiﬁed using the ImageJ software (NIH)
and converted into MBq using the equation: pixels=A
ln(Mbq) + B. A and B are parameters derived from
experimental calibration. Data were normalized with
respect to the enzyme concentration.
Electrophoresis mobility shift assay
Two complementary oligonucleotides (45nt each) were
mixed in 10mM Tris pH 8, 50mM NaCl and 1mM
EDTA and annealed by heating to 958C and slow cooling
to RT. GST–CTD was phosphorylated by incubation with
100ng of Cdk7/CycH or with 100ng of Cdk9/CycT1-298
or with 100ng of Cdk7/CycH and 100ng of Cdk9/
CycT1-298 in 50mM Tris pH 8, 0.1mM ATP and
10mM MgCl2 for 2h. Binding to DNA was tested by
mixing 40ng of DNA (2pmol) with 0.4, 2, 10 or 50
pmol of the diﬀerently phosphorylated GST–CTD in
20mM Tris pH 8, 20mM NaCl, 40mM KCl, 2mM
MgCl2, 0.2mM EDTA, 0.5mM DTT and 4% glycerol.
Samples were incubated on ice for 30min and then
loaded on a 6% native acrylamide gel. Gels were stained
using SYBR Green (Invitrogen).
Computational modelling
The CTD peptide
1YSPTSPSY
8 was manually built using
restraints from the NMR model of its complex with DNA
(21). It was subsequently docked into a 6 bp dsDNA by
superimposing Tyr1 and Tyr8 with the two quinoxaline
rings of triostin A (PDB 185D and 1VS2). The complex
was optimized using restraints from the NMR model of
the CTD/DNA complex and energy minimized using
Haddock (22,23).
Cdk7/CycH complex was modeled on pCdk2/CycA
structure (PDB 1QMZ) using Cdk7 and CycH
structures (PDB 1UA2 and 1KXU). CTD/DNA com-
plex was docked into Cdk7/CycH by superimposing
5SP
6 to the corresponding amino acids of the substrate
peptide co-crystallized with pCdk2/CycA (PDB 1QMZ).
The quaternary complex was energy minimized using
Haddock.
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UnphosphorylatedCTD binds DNA butCTD
phosphorylated by Cdks doesnot bindDNA
Previous work has shown that the CTD repeats
bind DNA by intercalating their tyrosines between
bases [Ka=100M
 1 in the interaction of the
YSPTSPSYSPTSPSY peptide with salmon testis DNA
(21,24,25)]. How this binding might be modiﬁed by CTD
phosphorylation is not known. CTD binding to DNA
was analysed by band shift using unphosphorylated
GST–CTD or GST-CTD phosphorylated by Cdk7/
CycH, Cdk9/CycT1-298 or by both Cdk7/CycH and
Cdk9/CycT1-298. Cdk7/CycH speciﬁcally phosphorylates
CTD-Ser5 while Cdk9/CycT acts on CTD-Ser2 (26–28).
Unphosphorylated CTD was found to bind DNA
(Figure 1A, lanes 2–5). Binding of CTD to DNA was
abolished following Ser5 phosphorylation by Cdk7/
CycH (Figure 1A, lanes 6–9) or following Ser2/Ser5 phos-
phorylation by Cdk7/CycH and Cdk9/CycT1 (Figure 1A,
lanes 14–17). Binding to DNA was reduced when CTD
was phosphorylated on Ser2 by Cdk9/CycT1 (Figure 1A,
lanes 10–13).
In its non-phosphorylated form the CTD is able to bind
DNA and this would be the form present in the context of
the pre-initiation complex. During transcription initiation
the CTD is phosphorylated primarily on Ser5 by Cdk7.
This event could promote initiation of transcription not
only disassembling the pre-initiation complex but also dis-
engaging CTD from DNA.
DNA-bound CTD isthe preferred substrate of Cdk7 but
notof Cdk9
RNA-Pol II in the pre-initiation complex is phosphory-
lated primarily by Cdk7 although both Cdk7 and Cdk9
are present in every stage of transcription. Does binding to
DNA lock CTD in a conformation recognised by Cdk7
but not by Cdk9?
Cdk7 and Cdk9 were tested for their ability to phos-
phorylate the CTD by itself and in complex with DNA.
The CTD/DNA complex is a better substrate for Cdk7
than the CTD alone (Figure 1B, lanes 1–5) but the CTD
alone is a better substrate for Cdk9 than the CTD/DNA
complex (Figures 1B, lanes 6–10). This suggests that CTD
bound to DNA confers substrate discrimination for the
two Cdks allowing preferential phosphorylation by Cdk7
and reducing phosphorylation by Cdk9.
Cdk2 phosphorylation by Cdk7/CycH was not aﬀected
by DNA (Figure 1B, lanes 11–15), conﬁrming that Cdk7 is
not a DNA-activated kinase and that the eﬀect observed
on CTD phosphorylation has to be ascribed to the CTD–
DNA complex formation and to the substrate presenta-
tion to Cdk7.
Amodel forCdk/CTD/DNA complex
To understand these diﬀerent recognition properties, a
model of the CTD/DNA complex was built based on
the NMR model of a dsDNA hexamer in complex with
the YSPTSPSY CTD peptide (21) and on the crystal struc-
tures of DNA–triostin A complex (PDB 185D and 1VS2)
(29–31). Triostin A is a bis-intercalating antibiotic mim-
icking the binding mode to DNA of single CTD repeats
(24). In the model of the DNA/CTD complex, Ser5 is
exposed but Ser2 is buried because of its proximity to
the buried tyrosine of the CTD (Figure 2A). The CTD
is in a beta-turn conformation generated by the DNA-
intercalating tyrosines (21).
The DNA/CTD complex was subsequently docked in
the Cdk7/CycH complex using as a guide information
from the crystal structure of Cdk2 in complex with a
Ser-Pro containing substrate peptide. The quaternary
complex was energy minimized. Ser5 could be easily
placed inside Cdk7 active site and in contact with catalytic
amino acids Asp137 and Lys139. Pro6 is in the proline
pocket generated by Val173, Val174 and Thr175 typical
of Ser-Pro directed kinases like Cdks (Figure 2B).
The quaternary complex was submitted to Protein
Interfaces, Surfaces and Assemblies service PISA at the
European Bioinformatics Institute (http://www.ebi.ac.uk/
msd-srv/prot_int/pistart.html) (32). Output values for
Figure 1. Eﬀect of phosphorylation on CTD binding to DNA and
eﬀect of DNA binding on CTD phosphorylation by Cdk7 and Cdk9.
(A) DNA binding by diﬀerent CTD phospho-isoforms. CTD phospho-
isoforms were generated by incubating CTD with the respective Cdk
in kinase buﬀer for 2h at RT. Increasing amounts of CTD and its
phospho-isoforms were then incubated with DNA in binding buﬀers
for 30min at 48C and then loaded on a 6% native acrylamide gel.
Unphosphorylated CTD binds DNA (lanes 2–5). No binding could
be detected using CTD phosphorylated by Cdk7 (lanes 6–9) or by
both Cdk7 and Cdk9 (lanes 14–17). Binding aﬃnity is strongly
decreased when CTD is phosphorylated by Cdk9 (lanes 10–13). (B)
CTD and CTD/DNA phosphorylation by Cdk7 and Cdk9. CTD/
DNA complex was generated by incubating CTD with a 44 bp
double-stranded DNA in binding buﬀer for 30min. Kinase assay was
performed by incubating 100 ng of each kinase and 5 mg of CTD, either
alone or in complex with increasing amount of DNA, in kinase buﬀer
for 5min at 208C. CTD phosphorylation by Cdk7 (lane 1) is increased
when CTD is in complex with DNA (lanes 2–5). Cdk9 prefers CTD
(lane 6) over CTD/DNA (lanes 7–10) as substrate. Cdk2 phosphoryla-
tion by Cdk7 is not aﬀected by DNA (lanes 11–15). Once phosphory-
lated, Cdk2 is able to phosphorylate Cdk7 (faint band just above Cdk2
band). Cdk7 is produced in baculo-viral-infected insect cells and repro-
ducibly puriﬁed as 70% monophosphorylated and 30% bisphosphory-
lated (18).
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complex formation are given in Table 1. Buried surface
area for CycH contacting Cdk7 (2470 A ˚ 2) is typical of
a stable protein–protein interaction (3250 A ˚ 2 for the
Cdk2/CycA complex and 1740 A ˚ 2 for the Cdk9/CycT1
complex). Buried surface area for CTD contacting Cdk7
(503 A ˚ 2) is typical of enzyme substrate interactions (930
A ˚ 2 for the Cdk2/substrate peptide complex) and is rein-
forced by the contacts with DNA. Polar contacts with
distance <3.5 A ˚ between Cdk7 and the CTD/DNA com-
plex are given in Table 2. No intermolecular bad contacts
were present in the quaternary complex.
The CTD/DNA complex inserts between the two kinase
lobes, both of which contribute to the binding via van der
Waals and polar interactions (Figure 2B). The catalytic
dyad Asp137-Lys139, responsible for the phospho-trans-
fer from ATP to the substrate, is conserved in all Cdks as
well as Gly21 that interacts with CTD via its peptide back-
bone. Other interactions involve Gln172 and four residues
of the b3-aC loop that is longer and more basic in
Cdk7 than in the other Cdks (residues 45–57 in Cdk7;
Figures 2B and 3). The interaction between the b3-aC
loop and DNA spans four bases of the same DNA
strand (Table 2). It is largely responsible for the calculated
Figure 2. CTD/DNA complex and model of interaction with Cdk7/CycH. (A) Two diﬀerent views of the CTD/DNA complex (left) and their surface
representation (right). DNA is in yellow, CTD in magenta, Ser5 in blue and Ser2 in grey. Ser5 is exposed while Ser2 is poorly accessible. (B) CTD/
DNA docked inside Cdk7/CycH active site. DNA is in yellow, CTD in magenta, Cdk7 in green and CycH in cyan. Polar interactions are represented
as dotted lines. CTD Ser5 is in contact with Cdk7 catalytic Asp137 and Lys139. A basic stretch of amino acids in Cdk7 contacts DNA backbone.
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complex and gives the correct orientation to the CTD/
DNA complex to accommodate Ser5 inside Cdk7 active
site. These interactions could increase Cdk7 aﬃnity for
CTD/DNA selecting it as a better substrate rather than
the CTD alone.
Docking of Ser2 into the catalytic site of Cdk7 generates
extensive clashes between the CTD/DNA complex and
Cdk7 activation segment and aD, aF and aG helices
(labeled in Figure 2B). Ser2 is next to the intercalating
Tyr1 and is poorly accessible.
The model identiﬁes Ser5 phosphorylation by Cdk7 as
the most likely site of modiﬁcation of the CTD/DNA
complex. Cdk9 has a diﬀerent b3-aC loop (residues
52–61) and a diﬀerent surface potential that would disfa-
vor its interaction with CTD/DNA (Figures 2 and 3).
When promoting transition from the pre-initiation to the
initiation stage of transcription, Cdk7 is part of the basal
transcription factor TFIIH. TFIIH has a signiﬁcantly
higher CTD phosphorylating activity than the Cdk7/
CycH complex (33). TFIIH contains DNA-binding fac-
tors, like the N-terminal zinc-ﬁnger domain of MAT1 or
the helicases XPB and XPD, which could participate in
increasing aﬃnity and activity of TFIIH for its substrate
CTD/DNA. It is possible that, in comparison to Cdk7/
CycH, the TFIIH complex would show an even greater
preference for CTD/DNA over CTD.
The CTD/DNA complex can be a substrate for Cdk7/
CycH for phosphorylation on Ser5 but it will be a poor
substrate for Cdk7/CycH for phosphorylation on Ser2
and for Cdk9/CycT for phosphorylation on both Ser5
and Ser2.
Cdk7b3-aCloop issufficient to favor phosphorylation of
CTD/DNA over CTD
The b3-aC loop is ﬂexible in many Cdk/cyclin complexes
and appears to be a region that allows response to diﬀer-
ent cyclins and inhibitors. In order to verify the role
of Cdk7 b3-aC loop in favoring phosphorylation activity
on CTD/DNA over CTD, a Cdk2 mutant (named
Cdk2-b3aC) was constructed substituting part of its
b3-aC loop
38DTET—EGVPS
46 with the corresponding
sequence in Cdk7 GHRTEAKDGVNR. Cdk2 was used
to compare with Cdk7 because it can be activated in vitro
by both its physiological partner CycA and by CycH, the
physiological Cdk7 cyclin, and because the E. coli expres-
sion system made the preparation of mutants easier than
with the baculovirus system for Cdk7. Likewise, Cdk7 is
activated in vitro by both CycH and CycA. Comparison of
those two Cdks, in complex with one or the other cyclin,
could uncover any involvement of cyclins in the preferen-
tial recruitment of CTD/DNA over CTD. The Cdk2-
b3aC mutant was further mutagenized to substitute part
of Cdk2 activation segment
162EVVTL
166 with the corre-
sponding sequence in Cdk7 QVVTR. This mutant, named
Cdk2-b3aCact, contains two additional mutations: Glu
to Gln (Gln172 in Cdk7) predicted to interact with the
CTD/DNA complex and Leu to Arg (Arg176 in Cdk7)
that is unique in Cdk7 and found to be involved in recog-
nition of the other Cdks when Cdk7 acts as Cdk-activating
kinase (CAK) (34).
Both Cdk7/CycH and Cdk7/CycA show a greater
activity in phosphorylating CTD/DNA than the CTD
alone (Figure 4, lanes 1–4). However, Cdk2/CycA
and Cdk2/CycH show a small preference for CTD as
substrate (Figure 4, lanes 5–8). The eﬀect is less pro-
nounced than that observed for Cdk9/CycT1
(Figure 1B). The observation that similar eﬀects are
observed with Cdks in complex with diﬀerent cyclins
leads to the conclusion that cyclins are not involved in
substrate selection.
Cdk2-b3aC/CycH and Cdk2-b3aC/CycA behave like
Cdk7/CycH and Cdk7/CycA showing that Cdk7-b3aC
loop is suﬃcient to favor CTD/DNA over CTD phos-
phorylation (Figure 4, lanes 9–12). No substantial diﬀer-
ences could be detected between Cdk2-b3aC and
Cdk2-b3aCact in complex with both CycH and CycA
(Figure 4, lanes 9–12 compared with lanes 13–16). Cdk7
Gln172 and Arg176 appear not to be essential for prefer-
ential CTD/DNA phosphorylation. In the model, Arg176
was not involved in any interaction with CTD/DNA.
Gln172, predicted to interact with CTD/DNA, is sub-
stituted by Glu in Cdk2 and by Arg in Cdk9 both capable
of partially reproducing Gln172 interactions shown in
Table 2.
The basic Cdk7 b3-aC loop, complementing the nucleic
acid backbone, directs the kinase action towards the
CTD–DNA complex.
Table 2. Polar contacts between Cdk7 and the CTD/DNA complex
Cdk7 CTD/DNA Distance
Gly21 O Thr4 OG 3.1
His47 NE2 PO-backbone 3.4
Arg48 NH1 PO-backbone 3.2
Arg48 NH2 PO-backbone 3.2
Lys52 NZ PO-backbone 2.8
Arg57 NH1 PO-backbone 3.3
Arg57 NH2 PO-backbone 2.9
Asp137 OD1 Ser5 OG 3.4
Asp137 OD2 Ser5 OG 3.0
Lys 139 NZ Ser5 OG 3.4
Gln 172 NE2 DNA base 2.9
Gln 172 OE1 Ser7 OG 3.3
Table 1. Solvent-accessible surface areas buried upon complex forma-
tion and energies of interactions in the Cdk7/CycH/CTD/DNA model
Molecule A Molecule B Buried
surface
area (A ˚ 2)
G
(Kcal/mol)
Cdk7 CycH 2470  12.4
Cdk7 CTD (YSPTSPSY) 503  1.9
Cdk7 DNA (6 bp) 798  7.1
CTD (YSPTSPSY) DNA (6 bp) 1011  1.3
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CTD-phosphorylating activity ofCdk9
Cdk9 phosphorylates CTD Ser2 following CTD Ser5
phosphorylation by Cdk7. It is tempting to speculate
that a docking site for CTD pSer5 on the Cdk9 surface
would help Cdk9 in selecting such substrate. I therefore
tested if prior phosphorylation of the CTD by Cdk7 made
it a better substrate for Cdk9. Comparison of Cdk9 activ-
ity on unphosphorylated CTD and pSer5-CTD (obtained
by previous incubation with Cdk7) did not show
signiﬁcant diﬀerences (Figure 5). The eﬀect of phosphor-
ylation by Cdk7 is not to make the CTD a better substrate
for Cdk9. CTD binding and release from DNA and initi-
ation transcription factors could be the event governing
the right timing of Cdk7 and Cdk9 action on CTD.
DISCUSSION
CTD binds dsDNA, but not ssDNA, in an unspeciﬁc non-
DNA sequence-dependent manner (24,35). The work
Figure 3. Primary and tertiary structure comparison for Cdk7, Cdk2 and Cdk9. (A) Sequence alignment. Cdk7 amino acids contacting the CTD/
DNA complex (distance <3.5 A ˚ ) are shown in red (polar contacts) and orange (van der Waals contacts). The model of CTD/DNA recognition by
Cdk7 was tested using Cdk2 mutants. Mutated residues are shown in green in the Cdk2 sequence. (B) Electrostatic surface representation. Black
circles delimitate b3aC loops of the three kinases. Diﬀerently from Cdk2 and Cdk9, the Cdk7 b3aC loop is positively charged.
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for unphosphorylated CTD. Phosphorylation by Cdk7
abolishes binding and phosphorylation by Cdk9 strongly
reduces binding. In the CTD/DNA complex, Ser2 is very
close to the DNA backbone and addition of a phosphate
group to it is not compatible with DNA binding. The
beta-turn conformation of the CTD bound to DNA is
centered on Ser5 and its phosphorylation would impede
maintenance of such a compact structure. The present
work shows that the preference for prior phosphorylation
by Cdk7 resides in the availability of Ser5 exposed to sol-
vent in the CTD/DNA complex while Ser2 is buried and is
not accessible. In the absence of DNA, phosphorylation of
Ser2 by Cdk9 proceeds with equal eﬃciency regardless of
whether Ser5 is phosphorylated or not. However, phos-
phorylation by Cdk7 on Ser5 results in a CTD that can no
longer bind DNA and hence making Ser2 available for
phosphorylation by Cdk9.
CTD-Ser7 has recently been found to become phos-
phorylated during the transcription cycle. Ser7 is buried
in the CTD–DNA model and access to it is not compatible
with CTD binding to DNA. Consequently, CTD phos-
phorylated on Ser7 should not be able to bind DNA.
This is in agreement with the observation that Ser7 phos-
phorylation is enriched on RNA-Pol II moving toward the
end of genes (36) and is involved in 3’ processing of tran-
scripts (37). CTD-Tyr1 is phosphorylated by the c-Abl
kinase (38), although a physiological role for this event
has not been elucidated. Phosphorylation on CTD-Thr4
has not been reported so far. In the proposed CTD–DNA
model, Tyr1 is intercalating between DNA base pairs
and is not accessible, while Thr4 is partially exposed to
the solvent.
Cdk7 and Cdk9 have diﬀerent phosphorylating propen-
sities for diﬀerent CTD repeats. Cdk7 phosphorylates
equally well N-terminal repeats (mostly consensus) and
C-terminal repeats (divergent from consensus sequence),
while Cdk9 has a strong preference for consensus repeats
and weak activity on C-terminal repeats (39,40).
pSer2-CTD, generated by Cdk9 action, has then some
unphosphorylated repeats still able to bind DNA, while
phosphorylation on Ser5 throughout the entire CTD by
Cdk7 completely abolishes DNA binding. This can be
ascribed to the compact beta-turn conformation, required
for DNA binding and largely determined by Pro6 and
tyrosines intercalation, that cannot accommodate a phos-
phate group on Ser5, which in contrast would force CTD
to change conformation.
CTD/DNA complex is a better substrate for Cdk7 than
free CTD. The model of the Cdk7/cyclin H/CTD/DNA
complex indicates that DNA recognition is achieved by
the Cdk7 b3-aC loop, and this observation is supported
by mutagenesis experiments. When bound to DNA, CTD
phosphorylation by Cdk9 is strongly reduced. In the
CTD/DNA complex, Ser2 is poorly accessible so that, fol-
lowing DNA binding, Cdk9 should be unable to phos-
phorylate it. The observation that some phosphorylation
did occur in the presence of Cdk9 indicates that, in these
experimental conditions, some CTD repeats are not
involved in DNA binding.
At the pre-initiation stage CTD is bound to DNA and
to several transcription factors (41). Those interactions
hide CTD to Cdk9 via steric hindrance and/or electro-
static repulsion. Only after such interactions have been
removed by Cdk7 phosphorylation of CTD, Cdk9 can
have access to it. Cdk7 does not make CTD a better
substrate for Cdk9 but only makes it available for further
modiﬁcations. After initiation, transcription pauses
before entering elongation phase. This pause, required
for RNA capping before elongation, could be ascribed
to a delay in Cdk9 phosphorylation of CTD. Initial
CTD phosphorylation by Cdk9 is a slow event while sub-
sequent phosphate additions are more rapid (40,42).
Figure 4. CTD and CTD/DNA phosphorylation by Cdk7, Cdk2 and
Cdk2 mutants in complex with either CycH or CycA. All reactions
were performed in duplicate. Root mean square deviations are shown
as error bars. Samples were loaded on 4–12% gradient SDS acrylamide
gels and visualized by autoradiography.
Figure 5. Cdk9 activity on CTD and pSer5-CTD. (A) CTD and pSer5-
CTD were loaded on SDS–PAGE. Phosphorylation by Cdk7/CycH
shifts the CTD band upwards. (B) Kinase assay. Cdk9/CycT1 phos-
phorylates equally well CTD and pSer5-CTD (generated by previous
incubation with Cdk7/CycH). No further incorporation of
32P could be
detected incubating pSer5-CTD with Cdk7/CycH indicating that the
previous reaction went to completeness.
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